IL1B and gout: Nevertheless, as the NF-κB and NLRP3 inflammasome pathways have emerged as therapeutic targets for the treatment of gout inflammation (Guo, Callaway & Ting, 2015; So & Martinon, 2017), the observed findings therefore strengthened the potential of the R14 peptide on the regulation in MSU crystals-induced production of IL-1β, the key aspect of gouty inflammation.